Skip to content

Author

J. Sampson

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Clinicopathologic mismatch in young-onset parkinsonism: Multiple system atrophy masquerading as a neurotransmitter synthesis disorder.

BACKGROUND Multiple system atrophy (MSA) is a progressive adult-onset synucleinopathy that remains difficult to diagnose clinically, particularly in younger patients and during early disease stages. Brainstem nuclei degeneration resulting in reduced monoamines in cerebrospinal fluid (CSF) analysis may further complicate diagnostic interpretation. OBJECTIVES To describe a clinicopathologic case of early-onset MSA found to have decreased CSF monoamines suggestive of a primary neurotransmitter synthesis disorder. MATERIALS AND METHODS Clinical records, neuroimaging findings, CSF neurotransmitter analysis, and postmortem neuropathologic examination were reviewed. RESULTS A 41-year-old woman developed rapidly progressive parkinsonism, dystonia, dysphagia, and speech impairment. Broad CSF analysis was significant for reduced homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and tetrahydrobiopterin, raising concern for a monoamine synthesis defect and prompting treatment for sepiapterin reductase deficiency (SRD). Despite directed therapy, neurologic decline continued. Postmortem examination demonstrated neuropathologic findings consistent with MSA, parkinsonian subtype (MSA-P). Early cortical and allocortical amyloid-β deposition corresponding to Thal phase 2 was also identified. No additional proteinopathies were present. CONCLUSION Degeneration of dopaminergic and serotonergic nuclei in MSA can reduce CSF monoamine metabolite levels and mimic disorders of neurotransmitter biosynthesis despite correlation with tetrahydrobiopterin levels. This case highlights a potential diagnostic pitfall when interpreting CSF neurotransmitter studies in adults with parkinsonism.

J. Newman, Jin Kyung Kim, Jeffrey J. Nirschl et al. · 0 citations
Open access Aug 2026

Generation of two induced pluripotent stem cell lines from Fabry disease patients carrying GLA mutations.

Fabry disease is a rare genetic disease caused by loss-of-function in the GLA gene. This gene encodes the lysosomal enzyme α-galactosidase A (α-Gal A). A deficiency of α-Gal A results in the globotriaosylceramide buildup throughout the major organs, which is associated with increased mortality from cardiac disease in patients with Fabry disease. Both females and males are affected by this X-linked disease. We generated and characterized induced pluripotent stem cell (iPSC) lines from peripheral blood mononuclear cells (PBMCs) of two female patients carrying a heterozygous GLA mutation. The two Fabry disease patient-derived iPSC lines are thoroughly characterized and genetically accurate, valuable human cell resources for preclinical research.

Debarun Patra, David G. T. Cabrera, Xiaochun Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.